When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KPTI - Karyopharm submits U.S. marketing application for Xpovio
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics (NASDAQ:KPTI) has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for XPOVIO (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with relapsed or refractory diffuse large B-Cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for stem cell transplantation, including CAR-T (chimeric antigen receptor modified T cell) therapy.
More news on: Karyopharm Therapeutics Inc., Healthcare stocks news,